A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule - Wikidata - awgldk - TriplyDB

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

http://www.wikidata.org/entity/Q56637378

about

Rivastigmine for Alzheimer's disease Rivastigmine for Alzheimer's disease Rivastigmine for Alzheimer's disease A practical algorithm for managing Alzheimer's disease: what, when, and why?Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative.Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice.Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer's disease.A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease Real-world evaluation of compliance and preference in Alzheimer's disease treatment.Alzheimer's disease and its treatment with a novel transdermal patch therapy: survey of caregiver experiences Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time.Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan.Present and prospective clinical therapeutic regimens for Alzheimer's disease.A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.Relative tolerability of Alzheimer's disease treatments Rivastigmine in Parkinson's disease dementia.Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.

P2860

Q24186551-97FCCD3E-9CE6-49D6-9950-14761C5175DF Q24187067-44C0F7B5-86B1-4E28-820F-B842C2F75817 Q24241686-CC792309-F408-462E-94C5-2562B42338D0 Q26859831-800758A6-F234-4A31-9D4B-2F3AC3F59C01 Q26863383-CC80E72E-6C45-497F-BBD4-87BFC60A75B4 Q26997299-469665B9-B04C-4A1F-B6E4-499BB34D6D61 Q33160127-DA96AEB1-403B-4C95-8A9B-6EEB7014FA82 Q33162691-17BF9A0F-971E-40A8-89AB-2AA99C9CE9C2 Q33370687-1068EE4D-F97B-481F-9E74-4936FB53FE25 Q33596451-A3911F5D-948E-48A3-9108-3DDB72205E96 Q33937187-E717CE4B-6A82-4BC8-9053-7215BC3A5B3F Q34032505-B6286833-6DD4-430D-A7E6-60FE29AD6EEA Q34051079-6FD43A59-0151-4301-99B7-88FD9CB42A87 Q34306253-A62775C8-3C03-4E50-A09A-CC3BDB00F435 Q34487826-E7AF153B-3987-4D98-B7A2-C5C262132BD6 Q34521949-D0DF3B36-9BDC-42A0-AA7C-CD147FEFE088 Q34542646-C30E3649-EB35-45CB-B43C-99CDD5D5D6D2 Q34543707-9D476ACD-EC5F-45B8-ACDA-C44C8691A7C3 Q35184995-89750C60-FD20-4DFB-9C30-256D1E4FEC15 Q35252005-3D24E3F0-FA93-463C-8F0C-8A3E799F8A7C Q35428213-17F7B710-E9B3-41D0-AA6C-62E18DB1B9FF Q35905814-29CBB967-D25D-4E8B-ABBA-64ED827A00C7 Q35988441-C7EB5D24-318E-40FF-8638-38F9170AA383 Q36165980-3652D448-3D81-450E-AAB4-BA4A791C0975 Q36261229-DD6798F4-C1FF-4A48-84CE-3B37964786C3 Q36264977-C9517138-00CE-42FA-9389-186EB63E6A27 Q36419735-D4EE68C7-5973-41EA-89E3-89CF5E1BC210 Q36467267-20F80120-B375-42F1-85E4-4F61750C8FCE Q36538811-C14AF73C-D878-48F2-8DBF-E6D56B707704 Q36766861-01152995-2A2E-41CF-B22E-91A3E9CC894B Q36876447-164EDE04-FE4A-4A0E-9841-151076F79E42 Q36998823-38E0A3DC-4C1D-4C3D-B70C-B2E288C0063C Q37070395-B6D1F7B7-C58C-427C-831E-3B4ADF9ACAF8 Q37193026-C0AA6845-772C-45E2-B4C1-46CEEF845F91 Q37225818-008FCC75-D02E-45DF-9E0A-98BB5588E7DB Q37232006-D0D08B6D-AD12-4C33-9C27-9B6DA3551CEB Q37255114-1A06E864-6102-4634-AAD2-3C1350D08CF4 Q37325828-B2C91AD4-36FF-40D2-A270-EBF4A661F5FD Q37358548-62A02D9F-1DF3-40C8-A29A-A6FFD081C989 Q37385577-0700B61A-912A-4A9E-B25A-85A0BCAC2A76

P2860

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

http://www.wikidata.org/entity/Q56637378

description

im Jahr 2007 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2007

@uk

name

A six-month double-blind, rand ...... vastigmine patchversus capsule

@en

A six-month double-blind, rand ...... vastigmine patchversus capsule

@nl

type

label

A six-month double-blind, rand ...... vastigmine patchversus capsule

@en

A six-month double-blind, rand ...... vastigmine patchversus capsule

@nl

prefLabel

A six-month double-blind, rand ...... vastigmine patchversus capsule

@en

A six-month double-blind, rand ...... vastigmine patchversus capsule

@nl

P1433

Q56637378-954A4F3D-D7B8-4EB5-B8A5-4A96400EA903

P1476

Q56637378-43A8FE52-2475-4398-9DBB-8B6DF2F68B65

P2093

Q56637378-27C2751E-B219-4566-AA85-B5841ECFE122

Q56637378-33BDC0C4-1D33-4F1C-8050-0054819E6842

Q56637378-40DEAA75-EA4A-474D-A912-16670B6F3075

Q56637378-454FBC8D-FFA4-4E0E-9D2F-92CB3646DDF6

Q56637378-8F07E159-3478-4236-AF15-F6D225B22708

Q56637378-B4031014-ED1B-4446-8483-6AFD69B67847

Q56637378-EC6EA1AF-497A-4B9A-8977-0FF8E7FCCBE6

P2860

Q56637378-08FBF4EB-C998-409B-9C21-CB301BDDC1B3

Q56637378-7E20F700-2126-4693-8A00-896B078E53B1

Q56637378-8229A479-B5BA-40B6-B737-697B5DEB2504

Q56637378-88491D33-8BFE-44F5-8508-6502E98EAACE

Q56637378-E569B5F0-B217-466C-B45D-E85C90B60228

P304

Q56637378-F8D36FCF-CB1A-40A1-A3E9-6DB47B805FB6

P31

Q56637378-6F9C8993-2457-411E-8FA9-0F195FBE83F9

P356

Q56637378-CABC33EF-3345-4146-8C55-BFA45DA3BF2B

P407

Q56637378-925CDCF4-CE98-4864-B652-708DB288BCB7

P433

Q56637378-ACFD9535-1DAF-44AF-9809-CABBDEB8346F

P478

Q56637378-B8AA5B61-700A-45CD-BA3C-B839C15B99A2

P50

Q56637378-3F7B5EFD-4804-4F37-91EB-47CFC14BF6DB

Q56637378-4733B407-01EC-4960-A44B-3CD1022A75AC

P577

Q56637378-ED18FF4E-5F73-4453-B7BA-60B0E7A15023

P5875

Q56637378-0C1109C2-E48F-4071-9B98-E6585111EA50

P698

Q56637378-F58B7302-72BB-409C-9AAF-210F8533487D

P921

Q56637378-6B3CDE65-E9CC-455D-A136-9EF3419F424D

P356

P1433

International Journal of Geriatric Psychiatry

P1476

A six-month double-blind, rand ...... vastigmine patchversus capsule

@en

P2093

Carl Sadowsky

http://www.w3.org/2001/XMLSchema#string

George Grossberg

http://www.w3.org/2001/XMLSchema#string

Jennifer Nagel

http://www.w3.org/2001/XMLSchema#string

Marco Onofrj

http://www.w3.org/2001/XMLSchema#string

Niels Andreasen

http://www.w3.org/2001/XMLSchema#string

Roger Lane

http://www.w3.org/2001/XMLSchema#string

Stefanie Zechner

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education.

Clock completion: an objective screening test for dementia.

A new rating scale for Alzheimer's disease.

P304

456-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GPS.1788

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey L. Cummings

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6427818

http://www.w3.org/2001/XMLSchema#string

P698

17380489

http://www.w3.org/2001/XMLSchema#string

P921